Physicians' Academy for Cardiovascular Education

Five years of PCSK9i - Lessons from practice: Which patients benefit most?

10' education - Sep. 30, 2020 - Prof. Erik Stroes, MD

Updates in the 2019 ESC/EAS guidelines for the management of dyslipidemia

10' education - Sep. 29, 2020 - Prof. François Mach, MD

The residual risk challenge in CVD: How important are triglycerides?

10' education - Sep. 25, 2020 - Prof. Ulf Landmesser, MD

A marriage of clinical trial results and imaging findings with icosapent ethyl

10' education - Sep. 21, 2020 - Fabrice Martens, MD, PhD, prof. Matthew Budoff, MD and prof. Gabriel Steg MD

Heart Failure, a multimorbid syndrome: An increasing challenge to manage

10' education - Sep. 21, 2020 - Prof. Carolyn Lam, MD

One year after the new ESC/EAS dyslipidemia guidelines

10' education - Sep. 17, 2020 - Prof. François Mach

New potassium binders for management of hyperkalemia in HF

10' education - Sep. 16, 2020 - Prof. Faiez Zannad, MD

No difference in outcomes after 5 years with anti-ischemic metabolic agent in patients after PCI

3' education - Sep. 15, 2020 - Prof. Freek Verheugt

Setting a patient on the right track following hospitalization for ADHF

15' education - Sep. 14, 2020 - Alexander Cadenbach, MD and prof. Mark Petrie, MD

The cardiology challenge to manage CV risk in diabetes

10' education - Sep. 9, 2020 - Prof. Nikolaus Marx, MD

Iron deficiency in patients with heart failure

10' education - Sep. 8, 2020 - Niels Grote Beverborg, MD, PhD

Incredible consistency between two SGLT2i trials in HFrEF

3' education - Sep. 7, 2020 - Milton Packer, MD

No clinical benefit from suspending ACEi/ARBs in hospitalized patients with COVID-19

3' education - Sep. 7, 2020 - Prof. Renato D. Lopes, MD, PhD

Updates in the 2020 AF guidelines

3' education - Sep. 2, 2020 - Prof. Isabelle van Gelder, MD

How to diagnose and treat amyloidosis?

10' education - Sep. 1, 2020 - Prof. Peter van der Meer, MD, PhD

SGLT2 inhibitors: a new foundation in heart failure or another diuretic?

10' education - Sep. 1, 2020 - Prof. Rudolf de Boer, MD, PhD

BP lowering should be considered irrespective of prior CVD or baseline SBP

3' education - Sep. 1, 2020 - Kazem Rahimi, MD

Advantages of the digital 2020 ESC Congress

3' education - Sep. 1, 2020 - Prof. Barbara Casadei, MD

Colchicine reduces primary outcome in chronic coronary disease

3' education - Aug. 31, 2020 - Mark Nidorf, MD

Triage strategy for outpatient management of PE patients based on HESTIA non-inferior to sPESI

5' education - Aug. 31, 2020 - Prof. Menno Huisman, MD

Five years of PCSK9i - Lessons from practice: Which patients benefit most?

10' education - Sep. 30, 2020 - Prof. Erik Stroes, MD
Prof. Stroes discusses the efficacy of PCSK9 and which patients benefit most from LDL-c lowering (combination) therapies.

Prof. Stroes discusses the efficacy of PCSK9 inhibitors and which patients benefit most from LDL-c lowering (combination) therapies.

Factor Xa inhibitor efficacious and safe in AF patients with extreme body weight

Literature - Sep. 29, 2020 - Boriani G, et al. - Thromb Haemost 2020

This posthoc analysis of the ENGAGE AF-TIMI 48 trial demonstrated no difference in efficacy and safety of edoxaban vs. warfarin in AF patients with extreme body weight compared to middle body weight.

Updates in the 2019 ESC/EAS guidelines for the management of dyslipidemia

10' education - Sep. 29, 2020 - Prof. François Mach, MD
Prof. Mach explains the recommendations for pharmacological LDL-c lowering as described in the 2019 ESC/EAS guidelines for the management of dyslipidemia.

Prof. Mach explains the recommendations for pharmacological LDL-c lowering as described in the 2019 ESC/EAS guidelines for the management of dyslipidemia.

SGLT2 inhibitor improves CV outcomes in HFrEF patients independent of SBP

Literature - Sep. 28, 2020 - Serenelli M et al. - Eur Heart J

In a subanalysis of the DAPA-HF study, dapagliflozin improved CV outcomes in HFrEF patients when compared to placebo, irrespective of baseline SBP.

Moderate and heavy alcohol consumption associated with hypertension

Literature - Sep. 28, 2020 - Mayl JJ et al. - J Am Heart Assoc. 2020

Compared to those who reported no alcohol intake, T2DM patients with moderate (>7 drinks/week) and heavy (>14 drinks/week) alcohol consumption had increased risk of elevated BP, hypertension grade I and hypertension grade 2.

The residual risk challenge in CVD: How important are triglycerides?

10' education - Sep. 25, 2020 - Prof. Ulf Landmesser, MD
What is the role of triglyceride-rich lipoproteins in residual risk in patients with ASCVD?

What is the role of triglyceride-rich lipoproteins in residual risk in patients with ASCVD?

Effects of PCSK9i on MACE and death as a function of baseline eGFR in patients with recent ACS

Literature - Sep. 22, 2020 - Tuñón J, et al. - Eur Heart J. 2020

This subanalysis of the ODYSSEY OUTCOME trial evaluated whether the effects of alirocumab, compared to placebo, on MACE and all-cause death are influenced by renal function in patients with recent ACS.

A marriage of clinical trial results and imaging findings with icosapent ethyl

Results of the EVAPORATE trial

10' education - Sep. 21, 2020 - Fabrice Martens, MD, PhD, prof. Matthew Budoff, MD and prof. Gabriel Steg MD
Three experts discuss detailed findings of the EVAPORATE study and how to interpret these. THe EVAPORATE trial examined the effect of icosapent ethyl on plaque formation and was a mechanistic study for the REDUCE-IT trial.

Three experts discuss the findings of the EVAPORATE study in detail and how to interpret these. The EVAPORATE trial examined the effect of icosapent ethyl on plaque formation and was a mechanistic study for the REDUCE-IT trial.

Heart Failure, a multimorbid syndrome: An increasing challenge to manage

10' education - Sep. 21, 2020 - Prof. Carolyn Lam, MD
Prof. Lam discusses important effects of comorbidities in HF patients and how these comorbidities may affect the use of treatments for HF.

Prof. Lam discusses important effects of comorbidities in HF patients and how these comorbidities may affect the use of treatments for HF.

A gap between guidelines and clinical practice for lipid management

Literature - Sep. 17, 2020 - Ray KK, et al. - Eur J Prev Cardiol 2020

Attainment of 2016 guideline-recommended risk-based LDL-c goal was 54% and 33% of 2019 risk-based LDL-c goal in patients on lipid-lowering therapy in primary and secondary settings.

FDA Fast Track designation for SGLT2i in patients with and without T2DM after acute MI

News - Sep. 17, 2020

The FDA has granted Fast Track designation for empagliflozin to reduce hospitalization for HF and mortality in patients with and without T2DM following an acute MI.

One year after the new ESC/EAS dyslipidemia guidelines

10' education - Sep. 17, 2020 - Prof. François Mach
Prof. Mach discusses how CV risk and circulating LDL-c can be reduced by lipid-lowering agents and current guideline recommendations to manage CV risk.

Prof. Mach discusses the concepts for lipid lowering treatment as defined in the 2019 ESC/EAS dyslipidemia guidelines.